|Bid||23.13 x 900|
|Ask||23.17 x 1000|
|Day's range||22.64 - 23.56|
|52-week range||16.47 - 30.14|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||22.72|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
UTHR vs. CORT: Which Stock Is the Better Value Option?